Does EVH pay a dividend and is it safe?

Evolent Health Inc (Class A) (EVH) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Consumer Discretionary / EVH / dividends

CSV (56) BLW (43) EVI (59) KLC (24) ⌘ Pro Terminal →

Evolent Health Inc (Class A) (EVH) Dividend Safety Gauge & 10-Year DRIP Compounder

$4.45 +3.49% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.47

Evolent Health Inc (Class A) (EVH) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $503.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EVH Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EVH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Evolent Health Inc (Class A) (NYSE: EVH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $4.45 (+3.49% 1D, market cap $503.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1009 tracked Consumer Discretionary issuers, EVH ranks #687 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EVH compare to CSV and BLW in the Consumer Discretionary sector?

▼

Within the Consumer Discretionary sector (Other Consumer Services), EVH carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of 21.3%, and ROIC of -26.3%. By comparison, CSV (Carriage Services Inc.) holds a D+ grade (56/100 RQD, P/E 10.9x, ROIC 29.8%, cap $555.1M) and BLW (Blackrock Limited Duration Income Trust) posts a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $415.3M). Among the 5-stock peer group, CSV leads on earnings multiple (10.9x) while CSV leads on capital efficiency (29.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EVH?

▼

Per EVH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001628908), Evolent Health Inc (Class A) generated $1.88B in revenue (-26.6% YoY), -$579.4M in net income, and $38.8M in free cash flow against $1.90B in total assets and $970.5M in total debt. Key quantitative strengths: Established market leader in Consumer Discretionary with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.47 (+0.44%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 2.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-6.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EVH)Realized 20D OHLCV Swing Band: ±12.4%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY EVH SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (23% of score)

20D Institutional Volume Accumulation (±12.4% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (23% of score)

FRED Regime × Technicals: 49% of 52W Range • RSI-14 at 53.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk6/20 pts (-14 pt drag)

Balance-sheet & 10-K footnote risk deducts 14 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$4.73+2.1% Next Q

Q2 (-2Q)

Grade D$4.83-10.4% Next Q

Q3 (-1Q)

Grade D$4.33+2.8% Next Q

Current

Grade D-$4.45-6.7% Hist 90D α

Trajectory: C- (51) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EVH Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EVH currently carries a cautious 43/100 (D-) rating due to SEC 10-K Forensic Risk (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Consumer Discretionary with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.17) and Max Pain ($4.67) forces dealer call-delta covering toward $7.23.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EVH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EVH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EVH)

✓Walkthrough of EVH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EVH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +13.81%▲ ASCENDING CHANNEL

2026-11-04O $4.30H $4.45L $4.30C $4.45VOL 1.43M

RES: $5.14SUP: $3.51SMA50: $4.17SMA200: $3.88

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EVH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EVH Butterfly Map → + Track EVH →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -26.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on EVH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EVH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EVH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EVH)

Consumer Discretionary Rank #687 of 1009 ⚔️ CSV vs EVH Full Matrix →

1. Head-to-Head Consumer Discretionary Peer Comparison (EVH vs. CSV, BLW, EVI, KLC)

Industry: Other Consumer Services (73 Tracked Issuers)

Across 1009 tracked Consumer Discretionary securities in the Roarable RQD universe, Evolent Health Inc (Class A) (EVH) ranks #687 by composite RQD confidence (43/100, grade D-) and #585 by equity capitalization ($503.1M). Within this direct 5-issuer industry benchmark cohort, CSV leads on earnings valuation at 10.9x trailing P/E, while CSV leads on capital efficiency and profitability with 29.8% ROIC and 35.1% gross margin. EVI currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with EVH at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EVH ACTIVE Evolent Health Inc (Class A)	D-	43/100	—	21.3%	-26.3%	+3.49%	$503.1M	Benchmark Subject
CSV Carriage Services Inc.	D+	56/100	10.9x	35.1%	29.8%	+0.17%	$555.1M	/csv-vs-evh →
BLW Blackrock Limited Duration Income Trust	D-	43/100	—	—	—	+0.17%	$415.3M	/blw-vs-evh →
EVI EVI Industries Inc.	C-	59/100	37.3x	30.4%	5.4%	+4.00%	$284.6M	/evi-vs-evh →
KLC KinderCare Learning Companies Inc.	E	24/100	—	—	-1.0%	+0.99%	$243.0M	/klc-vs-evh →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001628908 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Evolent Health Inc (Class A) (EVH) reported GAAP revenue of $1.88B (-26.6% vs. FY2024 revenue of $2.55B , and -4.5% cumulative change since FY2023) , GAAP net income of -$579.4M, operating cash flow of $38.8M, and free cash flow of $38.8M (+107.0% YoY). On the balance sheet, EVH closed FY2025 with $1.90B in total assets against $970.5M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.88B	-$579.4M	$38.8M	$38.8M	$1.90B	$970.5M
FY2024 (FY)	2024-12-31	$2.55B	-$93.5M	$18.8M	$18.8M	$2.54B	$490.5M
FY2023 (FY)	2023-12-31	$1.96B	-$142.3M	$142.6M	$142.6M	—	—

3. EVH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EVH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does EVH compare to CSV and BLW in the Consumer Discretionary sector?

What are the biggest fundamental strengths and SEC risk factors for EVH?

Where is EVH trading relative to its 50-day, 200-day, and 52-week technical levels?

EVH last traded at $4.45 (+3.49% on volume of 1,430,316 shares), positioning the stock +6.71% above its 50-day simple moving average ($4.17) and +14.69% above its 200-day simple moving average ($3.88). Across its 52-week range of $2.10 to $6.89, EVH sits at the 49.1% percentile with a 14-day RSI of 53.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.4% ($3.90 to $5.00).

Direct Sub-Reports: EVH RQD Cockpit EVH 12M Forecast EVH Earnings & Move EVH Dividends & DRIP EVH Insiders & 13F EVH Whale Options EVH Profit Sankey EVH News & Why

ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ SEC XBRL & RQD VERIFIED

EVH — Evolent Health Inc (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Evolent Health Inc (Class A) (EVH) earns a live Roarable RQD composite score of 43/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $4.45 (+3.49% 1D, market capitalization $503.1M).

Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -26.3%, gross margin of 21.3%, operating margin of -21.9%, and free cash flow yield of 8.08%.
Whale 13F & Options Flow (10/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (6/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of 2.34x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Evolent Health Inc (Class A) is a NYSE-listed issuer classified under the Consumer Discretionary sector and Other Consumer Services industry, profile.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Evolent Health Inc (Class A) (EVH) reported $1.88B in annual revenue (up from $2.55B in FY2024, -26.6% YoY) and -$579.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.96B revenue, -$142.3M net income) through FY2025, EVH scaled operating cash flow to $38.8M and free cash flow to $38.8M, backed by $1.90B in total assets against $970.5M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 43/100): Established market leader in Consumer Discretionary with deep daily trading liquidity. Free cash flow yield of 8.08% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $2.10 – $6.89 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -21.9% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or proprietary signal links are recorded (supply_chain: NONE; butterfly_links: empty). — for upstream/downstream dependencies or 2nd-order bottlenecks. Investors should note that the absence of mapped links means this dossier cannot identify ripple pathways; the cited sector classification (Consumer Discretionary / Other Consumer Services) is the only structural reference available.

Key Question #1: Can EVH sustain or expand its -21.9% operating margin and -26.3% ROIC against Other Consumer Services peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $1.88B and free cash flow of $38.8M, how will capital allocation balance growth reinvestment against $970.5M in total debt?
Key Question #3: How sensitive is EVH's equity valuation to Consumer Discretionary capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

EVH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Evolent Health Inc (Class A) (EVH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EVH Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 1d ago

Evolent Health, Inc Estimates – NYSE:EVH

TradingView report covering Evolent Health Inc (Class A) (EVH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 1d ago

1 unprofitable stock for long-term investors and 2 we avoid

The Globe and Mail report covering Evolent Health Inc (Class A) (EVH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH StockStory • 1d ago

3 Value Stocks with Warning Signs

StockStory report covering Evolent Health Inc (Class A) (EVH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST ad-hoc-news.de • 2d ago

Evolent Health stock gains 8.04 percent on the NYSE

ad-hoc-news.de report covering Evolent Health Inc (Class A) (EVH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 2d ago

Healthcare Technology for Providers Stocks Q2 Recap: Benchmarking Omnicell (NASDAQ:OMCL)

TradingView report covering Evolent Health Inc (Class A) (EVH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockStory • 2d ago

1 Cash-Producing Stock to Target This Week and 2 Facing Headwinds

StockStory report covering Evolent Health Inc (Class A) (EVH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockStory • 2d ago

1 surging stock with competitive advantages and 2 that underwhelm

StockStory report covering Evolent Health Inc (Class A) (EVH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo • 4d ago

American Well (AMWL) Surges 6.1%: Is This an Indication of Further Gains?

American Well (AMWL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EVH Bull vs. Bear Conversation Board — What's Your Call at $4.45?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EVH 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $5.25 (+22.1%)

📌 Pinned Debate

Positive 8.08% FCF yield and a reported 8.04 percent single-day gain suggest the market price may undervalue reported free cash flow.

Picked up a starter position in EVH in my $100K Virtual Cash book at $4.30. Positive 8.08% FCF yield and a reported 8.04 percent single-day gain suggest the market price may undervalue reported free cash flow.. Trading inside a $2.10–$6.89 52-week range with 8.08% FCF yield gives solid downside support if Other Consumer Services multiples expand this quarter.

RetailWhale_TX 🐂 BULL

@ForensicBear Shorting a 10/20 institutional whale-flow stock at $4.30 is dangerous when funds are rotating into Consumer Discretionary.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $3.61 (-16.0%)

Spot @ $4.30

Altman Z of 0.2, Debt/Equity of 2.34, and debt rising to $970.5M against $151.9M cash point to acute balance-sheet and solvency risk.

Here is the bear case nobody on the bull side wants to address on EVH: Altman Z of 0.2, Debt/Equity of 2.34, and debt rising to $970.5M against $151.9M cash point to acute balance-sheet and solvency risk.. At current EV/EBITDA multiples, even a small guidance miss in Other Consumer Services triggers a 12-15% air pocket.